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were subjected to thorough histopathological investiga-
tion, CTNNB1 mutation analysis, quantitative PCr, MlPA 
and FISH analyses for cytogenetic variables, and methy-
lome analysis. By univariable analysis, clinical factors 
(M-stage), histopathological variables (large cell compo-
nent, endothelial proliferation, synaptophysin pattern), and 
molecular features (chromosome 6q status, MYC amplifica-
tion, subgrouping) were found to be prognostic. Molecular 
consensus subgrouping (WNT, SHH, group 3, group 4) 
was validated as an independent feature to stratify patients 
into different risk groups. When comparing methods for the 
identification of WNT-driven medulloblastoma, this study 
identified CTNNB1 sequencing and methylation profiling 
to most reliably identify these patients. After removing 
patients with particularly favorable (CTNNB1 mutation, 
extensive nodularity) or unfavorable (MYC amplification) 
Abstract This study aimed to prospectively evalu-
ate clinical, histopathological and molecular variables for 
outcome prediction in medulloblastoma patients. Patients 
from the HIT2000 cooperative clinical trial were prospec-
tively enrolled based on the availability of sufficient tumor 
material and complete clinical information. This revealed 
a cohort of 184 patients (median age 7.6 years), which 
was randomly split at a 2:1 ratio into a training (n = 127), 
and a test (n = 57) dataset in order to build and test a risk 
score for this population. Independent validation was per-
formed in a non-overlapping cohort (n = 83). All samples 
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markers, a risk score for the remaining “intermediate 
molecular risk” population dependent on age, M-stage, pat-
tern of synaptophysin expression, and MYCN copy-number 
status was identified, with speckled synaptophysin expres-
sion indicating worse outcome. Test and independent vali-
dation of the score confirmed significant discrimination 
of patients by risk profile. Methylation subgrouping and 
CTNNB1 mutation status represent robust tools for the risk 
stratification of medulloblastoma. A simple clinico-patho-
logical risk score was identified, which was confirmed in a 
test set and by independent clinical validation.
Keywords Medulloblastoma · Biomarker · risk 
stratification · Prospective · Clinical trial cohort · 
Methylation profiling
Introduction
Medulloblastoma, the most frequent embryonal brain 
tumor in children, comprises four subgroups (WNT, SHH, 
group 3, group 4) with distinct cellular origin, histo-
pathological characteristics, pathogenetic events, demo-
graphical features, localization within the posterior fossa, 
and clinical behavior [1, 16, 17, 21, 26, 31, 32]. Current 
treatment stratification is based on patient age, M-stage, 
extent of initial surgery, and histopathological subtyping. 
The majority of infants (<3–5 years of age) do not receive 
radiotherapy, whereas most patients with residual tumor, 
metastatic disease and/or large cell or anaplastic histology 
receive intensified adjuvant radio-chemotherapy [5, 10, 22, 
27]. retrospective analyses have indicated that histopatho-
logical subtyping has strong prognostic value in certain 
patient subsets (e.g., desmoplastic vs. classic/anaplastic 
MB in infants) but not in others (e.g., anaplastic histology 
in standard-risk, non-metastatic cases [7, 27]).
Multiple studies have consistently shown that patients 
with WNT-driven medulloblastoma have a favorable prog-
nosis under standard treatment [2, 4, 23]. Novel treat-
ment protocols aim to test whether reduction of adjuvant 
therapy will decrease severe long-term side effects. The 
exact definition of WNT-driven medulloblastoma will be 
of paramount importance to the success of these studies. 
even a small number of wrongly assigned patients could 
lead to premature termination of the trial. Nuclear accumu-
lation of beta-catenin in tumor cells determined by immu-
nohistochemistry is currently used to identify WNT-driven 
tumors. As most of these tumors show activating CTNNB1 
mutations [20], the addition of sequencing for the assign-
ment to the WNT-group is discussed. Similarly, most of 
these tumors show monosomy 6 [23, 24]. With the pre-
sent study including subgrouping (e.g., by DNA methyla-
tion arrays), FISH or MlPA to detect monosomy 6, and 
Sanger sequencing of CTNNB1 (exon 3), we aim to pro-
vide a rationale as to which of these markers should best be 
applied in a clinical study setting.
The prognostic value of the molecular subgroups is a 
critical prerequisite for future clinical study design. Fur-
thermore, the most robust, specific and sensitive assays for 
molecular subgrouping in the clinical setting have yet to be 
determined. recent work has successfully utilized DNA 
methylation arrays for molecular subgrouping from stand-
ard formalin-fixed, paraffin-embedded (FFPe) tissue and 
demonstrated a high concordance with subgrouping based 
on gene expression profiling [9, 29].
Furthermore, the current study prospectively tested a 
large number of previously described prognostic or predic-
tive markers in medulloblastoma in a thoroughly controlled 
clinical trial cohort to prioritize markers to be considered 
for the next generation of clinical trials. After the identifica-
tion of useful high-risk markers such as MYC amplification, 
or low-risk markers such as the WNT-driven subgroup, we 
aimed to further substratify the large remaining group of 
“intermediate molecular risk” medulloblastoma.
Methods
Tumor material and patient characteristics
All patients diagnosed with medulloblastoma between 
September 2000 and March 2012 meeting the eligibility 
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criteria of either the HIT2000 trial (ClinicalTrials.
gov/NCT00303810) or being registered to the HIT2000 
registry with availability of sufficient tumor material, 
complete staging information, and complete clinical infor-
mation were enrolled in this study. Patients were eligible 
to the HIT2000 trial if they were diagnosed with medul-
loblastoma between 01.08.2000 and 31.12.2011 and were 
younger than 21 years at diagnosis (169/184 patients). 
Patients older than 21 (3/184 patients), patients receiving 
the treatment partially abroad (3/184 patients), or patients 
diagnosed between 01.01.2012 and 31.03.2012 (9/184 
patients) were registered to the HIT2000 registry. The 184 
patients included in this study represent approximately 
one-fifth of the patients reported to the HIT2000 trial and 
the HIT2000 registry in the corresponding period. Both 
the HIT2000 trial and the HIT2000 registry demand cen-
tral assessments of central reference histology (available 
in 100 % of the cases), neuroradiology and CSF-cytology 
Table 1  Patient characteristics 
(1) in the overall cohort, (2) in 
the subgroup M0, age >4, (3) 




 For one male patient M stage 
was not available, such that this 
patient could not be affiliated 
with any one of the treatment 
groups in this table
All patients M0, age at  
diagnosis >4
M1–M4 or M0, 
age at diagnosis <4
Number of patients 184a 88 95
Number of events/deaths 42/23 11/9 31/14
Median follow-up time (95 %CI) 1.78 (1.37; 2.19) 1.78 (1.21; 2.35) 1.82 (1.40; 2.24)
gender
 Male 121 58 62
 Female 63 30 33
Age at diagnosis
 Median 7.64 9.03 6.66
 range 0.29–38.88 4.56–38.88 0.29–21.87
M stagea age at diagnosis
 M0 and <4 23 – –
 M0 and >4 88 – –
 M1–M4 and <4 14 – –
 M1–M4 and >4 58 – –
 N/A 1 – –
Treatment stratum
 HIT 2000 BIS 4 22 – 22
 HIT 2000 AB 4 96 84 11
 MeT-HIT 2000 AB 4 48 1 47
 MeT-HIT 2000 BIS 4 before Am. 2 – 2
 MeT-HIT 2000 BIS 4 after Am. 11 – 11
 N/A 5 3 2
reference histology
 CMB 132 66 65
 DMB 37 19 18
 MBeN 6 – 6
 lCMB 1 – 1
 AMB 8 3 5
residual tumor
 <1.5 cm2 145 76 68
 >1.5 cm2 23 6 17
 N/A 16 6 10
PNeT5 risk group
 low risk 16 16 0
 Medium risk 52 52 0
 High risk 70 12 58
 None 46 8 37
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(complete and valid in 85 % of the patients). The HIT2000 
trial and the HIT2000 registry were approved by institu-
tional review boards, and informed consent was obtained 
from legal representatives of all patients. Data concern-
ing patient characteristics as well as follow-up informa-
tion were reviewed and verified at the trial center and are 
summarized in Table 1. Prospective tumor sample asser-
vation for biological research was initiated in 2009 and 
74 % of the samples analyzed in this study are derived 
from prospective collection. The 128 patients diagnosed 
between 01.01.2009 and 31.12.2011 represented 64 % of 
all medulloblastoma patients registered to HIT2000 in the 
corresponding time period. The focus on patients enrolled 
late into HIT2000 is the main reason for a relatively short 
median follow-up of the patients included in the present 
study.
Histopathological evaluation and classification
All specimens were diagnosed by at least two experi-
enced neuropathologists according to the WHO classifi-
cation of tumors of the CNS [19] at the german neuro-
pathological brain tumor reference center of the german 
Society for Neuropathology and Neuroanatomy (DgNN). 
In addition to standard hematoxylin and eosin staining, 
all cases underwent a silver impregnation for reticulin 
fibers. Immunohistochemistry was performed using an 
automated staining system (BenchMark XT, roche-Diag-
nostics, Mannheim, germany), with antibodies listed in 
Supplementary Table 1 in optimized concentrations and 
after adapted pre-treatment protocols for antigen retrieval. 
Cytological and histological parameters as well as the 
expression and distribution of these proteins were scored 
in all cases by two observers (for details, see Supplemen-
tary Table 1).
DNA methylation analysis
DNA methylation array data generation, data process-
ing, and copy-number analysis was essentially done as 
described [9]. Datasets of 169/181 patients from this cohort 
were presented in the previous publication. Details are 
given in Supplementary methods.
Analysis of β-catenin by immunohistochemistry 
and sequencing of CTNNB1
Staining of FFPe tissues for β-catenin expression using 
MAb 14, DNA extraction, and direct sequencing (Sanger) 
of exon 3 of CTNNB1 were performed as previously 
described [14]. Cases showing nuclear accumulation of 
β-catenin but no mutation of CTNNB1 were sequenced to 
identify alternative mutations in the APC binding sites of 
AXIN1 and AXIN2 as described before [3, 13].
Fluorescence in situ hybridization (FISH)
Multicolor interphase FISH analysis was performed as pre-
viously described [18, 24].
Multiplex ligation-dependent probe amplification (MlPA)
MlPA was performed as previously described [28], using 
the p301/302/303 medulloblastoma kit (MrC Holland, 
Amsterdam). PCr products were analyzed by ABI PrISM 
3100 genetic Analyzer (Applied Biosystems, Foster City, 
USA). Data were normalized against reference samples 
using the Coffalyser software (version 10). Normalization 
of probe signals to reference probes could not be performed 
due to genomically unstable genomes, which also displayed 
alterations in less frequently unbalanced genomic regions.
Statistical analysis
Univariable distribution of metric variables is described 
by median and range. Sensitivity and specificity of mark-
ers for the detection of WNT-driven medulloblastomas are 
given with exact 95 % confidence interval. The distribution 
of event-free survival (eFS) and overall survival (OS) were 
calculated according to the Kaplan–Meier method [12]. OS 
was calculated from date of diagnosis until death of the 
patient from any cause or last contact for patients alive, and 
eFS was calculated from date of diagnosis until an “event”, 
i.e., to date of first progression, relapse, occurrence of sec-
ondary malignancy, death of any cause, or last contact for 
patients without event.
For multivariable analyses, Cox regression models were 
used. estimated hazard ratios are provided with 95 % confi-
dence interval and p value of the likelihood ratio test. Score 
building to analyze the prognostic value of potentially 
prognostic factors is fully described in Supplementary 
methods. Variables included for analyses are summarized 
in Supplementary Table 2. A score with two risk groups 
(favorable versus unfavorable) with respect to eFS was 
built in the training dataset. Internal validation in the test 
dataset as well as independent validation in the ICgCPed-
Brain medulloblastoma cohort was performed by assessing 
whether the score significantly discriminates patients by 
risk profile [11]. The following two null hypotheses were 
tested by two-sided log-rank tests for difference on a two-
sided significance level of 5 %. Null hypothesis 1: the eFS 
does not differ between favorable and unfavorable patients 
from the test dataset. Null hypothesis 2: the eFS does not 
differ between favorable and unfavorable patients from the 
141Acta Neuropathol (2014) 128:137–149 
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ICgCPedBrain medulloblastoma cohort. Adjustment for 
multiple testing is done by means of the Bonferroni–Holm 
method [8].
The remaining analyses were regarded as explorative, 
and p values are given descriptively to detect and study 
meaningful effects.
Table 2  Univariable Cox regression models: estimated hazard ratio (Hr) for event-free survival with 95 % confidence interval (CI) and p value 
of the likelihood ratio test for omnibus test
NE not estimable (because there are no events in this group)
* p value of the likelihood ratio test for omnibus test. For pairwise comparisons, confidence intervals instead of p values are given (p value of 
Wald test ≤0.05 if and only if confidence interval does not contain 1)
Clinical and biological variables Available cases Hr 95 % CI p*
M stage 183 0.030
 M1 vs. M0 20 vs. 111 1.822 0.721–4.605
 M2/3 vs. M0 52 vs. 111 2.417 1.254–4.660
 M1 vs. M2/3 20 vs. 52 0.754 0.298–1.907
reference confirmed M0 stage 184 0.010
 No vs. yes 73 vs. 111 2.231 1.208–4.122
Treatment stratum 179 0.003
 HIT 2000 BIS 4 vs. HIT 2000 AB 4 22 vs. 96 2.758 1.066–7.136
 MeT-HIT 2000 AB 4 vs. HIT 2000 AB 4 48 vs. 96 3.082 1.428–6.653
 MeT-HIT 2000 BIS 4 after amendment vs. HIT 2000 AB 4 11 vs. 96 3.763 1.190–11.878
 MeT-HIT 2000 BIS 4 before amendment vs. HIT 2000 AB 4 2 vs. 96 18.858 3.988–89.163
 HIT 2000 BIS 4 vs. MeT-HIT 2000 AB 4 22 vs. 48 0.895 0.367–2.180
 MeT-HIT 2000 BIS 4 after amendment vs. MeT-HIT 2000 AB 4 11 vs. 48 1.220 0.407–3.660
 MeT-HIT 2000 BIS 4 before amendment vs. MeT-HIT 2000 AB 4 2 vs. 48 6.118 1.353–27.663
 MeT-HIT 2000 BIS 4 after amendment vs. HIT 2000 BIS 4 11 vs. 22 1.364 0.397–4.689
 MeT-HIT 2000 BIS 4 before amendment vs. HIT 2000 BIS 4 2 vs. 22 6.839 1.364–34.278
 MeT-HIT 2000 BIS 4 b. Amendment vs. MeT-HIT 2000 BIS 4 a. Amendment 2 vs. 11 5.015 0.894–28.149
Presence of large cell component 184 0.022
 Yes vs. no 7 vs. 177 4.267 1.511–12.056
Presence of endothelial proliferation 184 0.035
 No vs. yes 59 vs. 125 0.448 0.199–1.009
Pattern of synaptophysin expression 184 0.006
 Speckled yes vs. no 55 vs. 129 2.651 1.369–5.136
Categorized TOP2A copy number 155 0.003
 >2.7 vs. < 2.7 44 vs. 111 0.291 0.113–0.746
TOP2A copy-number (continuous) 155 0.673 0.452–1.002 0.039
6q status (array-based) 172 0.031
 gain vs. bal 16 vs. 143 0.717 0.220–2.332
 loss vs. bal 13 vs. 143 Ne –
6q status (FISH) 176 0.034
 gain vs. bal 19 vs. 141 0.381 0.092–1.584
 loss vs. bal 16 vs. 141 0.183 0.025–1.337
 loss vs. gain 16 vs. 19 0.480 0.043–5.307
MYC status (FISH) 181 0.036
 Amplif vs. bal 6 vs. 175 3.711 1.317–10.453
450k subgrouping 175 0.007
 group_3 vs. group_4 46 vs. 72 2.037 1.014–4.089
 SHH vs. group_4 42 vs. 72 0.895 0.382–2.099
 SHH vs. group_3 42 vs. 46 0.440 0.187–1.032
 WNT vs. group_4 15 vs. 72 Ne –
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Results
Prospective testing of single markers in a training, test 
and independent validation cohort
A total of 66 single markers were prospectively assessed in 
this study in a clinical trial cohort of 184 patients (Supple-
mentary Table 2). Survival association revealed 12 markers 
to be statistically associated (p ≤ 0.05) with eFS (Table 2), 
and 15 markers with OS (Supplementary Table 3). Statisti-
cally relevant variables (p ≤ 0.05) for eFS included clinical 
(M-stage), histopathological (presence of large cell com-
ponent, endothelial proliferations, speckled synaptophysin 
expression), and molecular features (MYC amplification, 
chromosome 6q status, TOP2A copy-number (located on 
17q), and methylation-based subgrouping. For OS, the 
same parameters were prognostic with the exception of 
M-status and presence of endothelial proliferation. In addi-
tion, histopathological classification according to the cur-
rent WHO classification, chromosome 17p, and 10q status 
were also found to be prognostic of OS.
Molecular subgroups are strongly associated with clinical 
outcome
We recently applied the Illumina 450k BeadChip array to 
subgroup medulloblastomas [9]. Interestingly, out of our 
centrally pathology-reviewed study samples, two outlier 
samples were detected (Supplementary Fig. 1a, Supple-
mentary Methods), one atypical teratoid rhabdoid tumor 
(AT/rT), which however lacked some morphological fea-
tures of an AT/rT requested by the WHO classification 
(Supplementary Fig. 1b), and one ependymoblastoma, 
the latter one of which was removed from the study after 
careful re-examination of the morphology (Supplementary 
Fig. 1c).
As demonstrated in Fig. 1a, the predicted subgroups of 
179 tumors not only recapitulated the previously reported 
distribution, but were also associated with the expected 
enrichment of cytogenetic aberrations. As such, copy-num-
ber aberrations of chromosome 17 were strongly enriched 
in groups 3 and 4, monosomy 6 was almost exclusively 
confined to WNT-driven tumors, whereas 9q deletions were 
strongly enriched in SHH-driven tumors, and 10q deletions 
were mostly distributed across SHH-driven and group 3 
tumors. MYC amplifications were essentially restricted to 
group 3 (only one out of 8 patients had group 4 tumor), 
and MYCN amplifications to SHH and group 4 tumors. 
Methods to assess cytogenetic aberrations were compared 
against each other whenever results obtained by at least 
two methods were available (Supplementary Table 4). gen-
erally, for broad aberrations (e.g., 6q loss), analysis using 
the 450 k array appeared to be most reliable (probably not 
surprising since many more data points are generated than 
with any other method), whereas for focal amplifications 
(e.g., MYC or MYCN, the sensitivity of FISH appeared to 
be the best, while not lacking specificity). Furthermore, 
all samples from the WNT subgroup harbored mutations 
in exon 3 of the CTNNB1 gene and no such mutations 
were observed in any “non-WNT” sample. Finally, clini-
cal markers such as M-stage and histopathological subtype 
were also strongly subgroup-enriched, as previously dem-
onstrated [16, 21].
When integrating subgroup information with clinical 
outcome data across the entire cohort [median follow-up 
21.4 months after diagnosis (range 0.0–111.3)], we could 
prospectively validate the prognostic value of molecular 
subgroups both for eFS (Fig. 1b, c) and OS (Supplemen-
tary Fig. 2). Kaplan–Meier analysis revealed that molecular 
subgrouping robustly stratifies patients into the risk groups 
WNT, SHH, group 3 and group 4 (5-year event-free sur-
vival (eFS) 1.00 (WNT) vs. 0.66 ± 0.11 (SHH) vs. 0.57 
(group 4) ± 0.10 vs. 0.44 ± 0.11 (group 3), p = 0.019, 
Fig. 1b; 5-year overall survival (OS) 1.00 (WNT) vs. 
0.81 ± 0.15 (SHH) vs. 0.70 ± 0.10 (group 4) vs. 
0.56 ± 0.12 (group 3), Supplementary Fig. 2, p = 0.049). 
Pairwise comparisons are given in Table 3. Furthermore, a 
multivariable Cox regression model including molecular 
subgrouping together with age at diagnosis, M-stage, resid-
ual disease, histopathological subtype, and MYC status 
only selected molecular subgrouping and M-stage for the 
final model indicating that subgrouping will be an impor-
tant asset for eFS prediction in future studies (Table 4). For 
OS prediction, only subgroup remains in the model (Sup-
plementary Table 5). Interestingly, the prognostic power of 
molecular subgroups appears to be particularly pronounced 
in infants (Supplementary Fig. 3a, c, although due to small 
sample size not statistically significant), possibly explain-
ing why the study by Schwalbe et al. [29] did not identify 
outcome differences between SHH, group 3 and group 
4 patients in a cohort of patients >4 years of age (compa-
rable to Supplementary Fig. 3b, d). group 3 seems to be 
associated with inferior outcome in infants (larger series or 
follow-up time will be needed to confirm) even within the 
M0 group further indicating that group 3 infants might be 
Fig. 1  Molecular subgrouping of medulloblastoma samples. a 
Molecular subgroups of medulloblastoma samples for which suffi-
cient material was available (n = 179) as assessed by unsupervised 
k-means consensus clustering of 450k methylation array data. A 
large subset of this data (n = 169) was previously presented in [9]. 
b Associations of molecular subgroups with eFS across all treatment 
groups and comparison with c the molecular stratification planned for 
the upcoming european cooperative medulloblastoma trial PNeT5 
(low risk = M0 and residual tumor <1.5 cm2 and CTNNB1 muta-
tion positive; high risk = either M1–M4 or MYC/MYCN amplified or 
residual tumor >1.5 cm2 or anaplastic or large cell histology; standard 
risk = all remaining cases)
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considered high risk even if no other high-risk marker is 
present (Supplementary Figs. 3e, f, 5).
CTNNB1 exon 3 mutation status is the most robust single 
marker to identify WNT medulloblastoma
We sought to identify the most specific and sensitive marker 
for WNT-subgroup patients in an unbiased way in this pro-
spective clinical trial cohort, and compared beta-catenin 
immunohistochemistry, chromosome 6 assessment (by 
450k), and CTNNB1 exon 3 sequencing with the methyla-
tion grouping (Fig. 2a). Importantly, all cases predicted to be 
WNT-driven medulloblastomas by molecular subgrouping 
had an exon 3 mutation in CTNNB1, and no CTNNB1 muta-
tion was found in a non-WNT medulloblastoma (specific-
ity = 1.000; 95 % CI 0.977–1.000 and sensitivity = 1.000; 
95 % CI 0.782–1.000 when considering CTNNB1 mutation 
status as the “gold standard”, Fig. 2b). All but one of the 
patients with a CTNNB1 exon 3 mutation remained event-
free to date during follow-up. Of 22 tumors that showed 
nuclear accumulation of β-catenin in >5 % of tumor cells, 
CTNNB1 mutation status was available for all 22, and sub-
group information was available for 19 samples (Fig. 2c). 
Of these, 18/22 (82 %) were mutated, and 15/19 (79 %) 
were predicted to be WNT by methylation subgrouping. 
All four patients with immunopositive, but CTNNB1 wild-
type tumors, clearly belonged to a different subgroup (three 
group 3, one group 4), and two had an event during follow-
up, further indicating that immunohistochemical assessment 
may be less specific to identify a low-risk population than 
CTNNB1 mutation status (specificity = 0.976; 95 % CI 
0.940–0.993 and sensitivity = 1.00; 95 % CI 0.782–1.000). 
Of 13 patients who had a tumor with 6q deletion (as meas-
ured by 450k), 12 were of the WNT subgroup and one of 
group 4 indicating good specificity, but relatively poor 
sensitivity of this surrogate marker (specificity = 0.994; 
95 % CI 0.965–1.000 and sensitivity = 0.800; 95 % CI 
0.519–0.957, Fig. 2d). Of 10 patients who had a tumor with 
both 6q deletion (as measured by FISH) and accumulation 
of β-catenin in >5 % of tumor cells, 9 were of the WNT 
subgroup and one of group 3 indicating good specificity, 
Table 3  Univariable log-rank test on difference for all pairwise 
comparisons of molecular subgroups with respect to event-free sur-
vival (eFS) and overall survival (OS)
* Two-sided p value of the log-rank test on difference
Available cases eFS OS
p* p*
group_3 vs. group_4 46 vs. 72 0.048 0.076
SHH vs. group_4 42 vs. 72 0.807 0.431
WNT vs. group_4 15 vs. 72 0.083 0.260
SHH vs. group_3 42 vs. 46 0.052 0.039
WNT vs. group_3 15 vs. 46 0.018 0.095
WNT vs. SHH 15 vs. 42 0.080 0.326
Table 4  Multivariable Cox regression model for event-free survival 
including molecular subgrouping, age at diagnosis, M stage, residual 
disease, histopathological subtype and MYC status
estimated hazard ratio (Hr) with 95 % confidence interval (CI) and p 
value of the likelihood ratio test for omnibus test
NE not estimable (because there are no events in this group)
* p value of the likelihood ratio test for omnibus test. For pairwise 
comparisons, confidence intervals instead of p values are given (p 
value of Wald test ≤0.05 if and only if confidence interval does not 
contain 1)
*** N/S not selected in the final multivariable model (inclusion: p 
value Score test ≤0.05, exclusion: p value likelihood ratio test >0.1)
Variable Available cases Hr 95 % CI p*
Age at diagnosis N/S***
 <4 vs. >4 33 vs. 133 – –
M_Stage 0.045
 M1–M4 vs. M0 66 vs. 100 2.064 0.998–4.269
residual tumor N/S***
 >1.5 cm2 vs. 
<1.5 cm2




33 vs. 119 – –
 MBeN vs. classic 5 vs. 119 – –
 Anaplastic vs. 
classic
8 vs. 119 – –
 large cell vs. classic 1 vs. 119 – –
MYC_status N/S***
 Amplified vs. bal-
anced
7 vs. 159 – –
450k subgrouping 0.032
 group_3 vs. 
group_4
45 vs. 70 2.141 1.042–4.400
 SHH vs. group_4 38 vs. 70 1.329 0.497–3.556
 SHH vs. group_3 38 vs. 45 0.621 0.234–1.644
 WNT vs. group_4 13 vs. 70 Ne –
Fig. 2  Comparison of markers for the identification of WNT-driven 
medulloblastomas. eFS for patients with WNT-subgroup tumors as 
assessed by a 450k methylation analysis, b CTNNB1 exon 3 sequenc-
ing, c β-catenin immunohistochemistry (>5 % positive nuclei), d 6q 
deletion by 450 k. e Venn diagram for assessment of WNT-subgroup 
markers and their interrelationship: number of WNT-patients accord-
ing to 450 k-array subgrouping, exon 3 mutation in CTNNB1, beta-
catenin IHC (nuclear accumulation of beta-catenin in >5 % of tumor 
cells) and 6q deletion (as assessed by 450k)
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Fig. 3  Identification and test of a risk score. a example of speckled 
synaptophysin positivity in contrast to b diffuse synaptophysin posi-
tivity. c eFS in the training cohort in which the risk score was estab-
lished. d eFS in the test cohort, e OS in the training cohort in which 
the risk score was established, f OS in the test cohort
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but sensitivity of this combined surrogate marker was also 
poor as far as this can be deduced from this relatively small 
series (specificity = 0.994; 95 % CI 0.966–1.000 and sen-
sitivity = 0.696; 95 % CI 0.471–0.868). A Venn diagram 
summarizing the results of the different WNT testing meth-
ods is shown in Fig. 2e. Furthermore, a cross-table directly 
comparing all these variables is provided in Supplementary 
Table 6. AXIN1 and AXIN2 mutations were not found in 
tumors of this series.
Further stratification of an “intermediate molecular risk” 
cohort
To develop a risk score for eFS, random attribution to 
training (n = 127) and test (n = 57) sets was done at a 2:1 
ratio (Supplementary Table 7). In our discovery approach, 
we focused on intermediate molecular risk group patients 
(non-WNT, non-medulloblastoma with extensive nodular-
ity (MBeN), non-MYC amplified) to develop a prognos-
tic index, since this remains a relatively large population 
of patients that has proven difficult to further stratify in a 
clinical setting.
In this cohort, speckled synaptophysin expression 
(Fig. 3a) was selected for the prognostic index aside from 
age, M-stage, and MYCN status. According to the result-
ing score, patients are classified as favorable or unfavora-
ble. WNT and MBeN patients were classified as favorable, 
patients with MYC amplification as unfavorable. In the 
training cohort (n = 127), n = 84 patients were classified 
as favorable and n = 42 as unfavorable by the final score 
(p < 0.001). One patient could not be allocated due to miss-
ing MYCN status.
reassuringly, the survival associations for eFS that 
were seen when developing the score in the training 
cohort (Fig. 3d, p < 0.001) were also observed in the test 
cohort (favorable: n = 42, unfavorable: n = 15, p = 0.013, 
adjusted p value p = 0.026, Fig. 3c) concluding that eFS of 
patients with favorable classification is significantly higher 
than eFS of patients with unfavorable classification. Simi-
larly, when performing a multivariate analysis across the 
entire cohort including speckled synaptophysin expression, 
age at diagnosis, M stage, residual disease, histopathologi-
cal subtype and MYC status, only synaptophysin pattern, 
age, and M-stage were selected for the final model (Sup-
plementary Table 8). For OS the score was only able to seg-
regate favorable from unfavorable patients in the training 
cohort (Fig. 3e), but not in the test cohort (Fig. 3f), which 
might be due to the relatively short follow-up time and/
or the group size. A re-analysis with updated follow-up 
data will be made available to the neurooncology commu-
nity when a median follow-up of 5 years will be reached. 
Additionally, the risk score was independently validated 
in the completely non-overlapping ICgCPedBrain cohort 
(n = 83) of well-annotated intermediate molecular risk 
samples confirming that eFS of patients with favorable 
classification is significantly higher than eFS of patients 
with unfavorable classification (favorable, n = 52; unfa-
vorable, n = 24; p = 0.021; adjusted p value p = 0.026; 
Supplementary Fig. 4c). For seven patients, informa-
tion on risk classification was missing. In the ICgCPed-
Brain cohort robust risk stratification with respect to OS 
was observed (p = 0.031, Supplementary Fig. 4d). As an 
independent validation step, another investigator from 
our consortium analyzed speckled synaptophysin in the 
ICgCPedBrain cohort (clinical information summarized 
in Supplementary Table 9) and found a similar association 
with inferior survival (Supplementary Fig. 4).
Discussion
Many studies have now demonstrated that medulloblastoma 
does not represent a single disease entity but consist of at 
least four molecular consensus subgroups and five histo-
pathological subtypes. More recently, the treatment of cer-
tain subgroups was adapted to risk, for example in infants 
according to histology, and is currently being adapted 
for WNT-driven medulloblastoma. In this study, we vali-
dated the prognostic value of clinical, histopathological 
and molecular markers in a prospective cohort of patients 
treated according to the multicenter HIT2000 medullo-
blastoma trial. In addition to established markers, we show 
for the first time in a prospective clinical trial cohort that 
includes infants (after the report by Schwalbe et al. [29] 
focusing exclusively on older children) that molecular 
subgrouping may serve as a reliable tool for patient strati-
fication. This is of immediate clinical impact for upcom-
ing trials aiming to test the feasibility of reducing therapy 
intensity in WNT-driven medulloblastoma. The subgroup 
information is also of central importance to enable recruit-
ing patients to SHH inhibitor trials at relapse, a condition 
for which a phase III trial started recruiting patients in the 
second half of 2013 (clinicaltrials.gov, ID: NCT01708174). 
After screening for SHH subgroup affiliation, the actual 
genetic hit in the SHH pathway should be deciphered, since 
it has become evident that especially children older than 
4 years of age frequently have mutations downstream of 
Smoothened rendering these tumors primarily resistant to 
SMO inhibition [15, 25]. Since 2005, infants are treated in a 
risk-adapted way according to their histology. Patients with 
desmoplastic or extensive nodular tumors show a better sur-
vival even after reduction of therapy [27]. These tumors are 
typically SHH-driven. However, some studies indicated that 
the SHH subgroup contains a significant fraction of clas-
sic or large cell tumors, rendering desmoplasia a surrogate 
marker with relatively high specificity, but poor sensitivity. 
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In this cohort, 36 of 42 medulloblastomas of the SHH meth-
ylation subgroup were diagnosed as DMB (desmoplastic 
medulloblastoma)/MBeN, 4 of the classic and 2 of the ana-
plastic subtype. In infants, the overlap of SHH subgroup and 
DMB/MBeN histology was 100 %. In older patients, how-
ever, the sensitivity of desmoplastic histology as a surro-
gate marker for the SHH subgroup seems to be much lower. 
Additionally, 6 tumors were diagnosed as desmoplastic 
which molecularly belonged to group 3 or group 4 (three 
each). Thus, molecular subgrouping adds significantly to the 
identification of clinically relevant subgroups. Therefore, 
we strongly suggest incorporating molecular subgrouping 
assessed either by gene expression profiling, nanoString, or 
DNA methylation profiling, into the next revised version of 
the WHO classification of CNS tumors.
Upcoming studies aiming to reduce treatment intensity 
for WNT-driven medulloblastoma comprise an impor-
tant step to increase quality of survival in medulloblas-
toma patients and de-escalate therapy in this disease for 
a substantial proportion of patients. Strict stopping rules 
require a very cautious patient selection to prevent failure. 
Traditionally, WNT activation was primarily assessed by 
immunohistochemistry [4]. A recent study by Schwalbe 
et al. [29] suggested that methylation subgroup and IHC 
were in good concordance. In our study, we have indica-
tion that some IHC-positive tumors may show relapses and 
do not cluster with WNT tumors by methylation profiling, 
although the number of investigated tumors was low. Our 
data indicate that methylation profiling and/or mutation 
analysis will add to the reliable identification of WNT-
driven medulloblastomas. This approach will certainly 
increase the chances for the therapy de-escalation studies in 
WNT medulloblastomas to become a success.
After removing the relatively small groups of patients 
with very favorable prognosis (WNT-activated and MBeN) 
and high-risk patients (MYC amplification) from this clini-
cal trial cohort, further stratification of the remaining “inter-
mediate molecular risk” group was attempted, since this 
group of patients is a challenge for study groups currently 
planning therapeutic concepts for the next generation of 
clinical trials. Aside from M-stage, which has long been 
used in the clinic to stratify these patients, we have iden-
tified speckled synaptophysin expression to be associated 
with inferior outcome. Together with age and M-stage, this 
marker was selected in an unbiased score formation and 
performed well in both our training and test cohorts, as well 
as in an independent validation cohort of patients of this risk 
group. Speckled synaptophysin is a typical feature found in 
large cell medulloblastomas. This variant is rare but strongly 
related to poor outcome and MYC amplification [19]. How-
ever, the proportion of tumors with speckled synaptophysin 
expression is much larger than the fraction of tumors show-
ing MYC amplification or large cell components. Thus, our 
data suggest that this protein marker warrants further pro-
spective testing in a clinical trial context.
In conclusion, we propose the following approach for 
the comprehensive diagnostic workup of medulloblastoma 
(summarized in Supplementary Fig. 5):
1. Determining the clinical stage (residual tumor, metas-
tasis), histopathological subtype and molecular sub-
group (either by gene expression profiling, nanostring, 
or by DNA methylation profiling).
2. WNT-activated subgroup: positive for any two of IHC 
for nuclear β-catenin accumulation, CTNNB1 mutation 
analysis, or molecular subgroup.
3. SHH subgroup: two prognostically diverging sub-
groups have to be identified, TP53 mutant vs. wild-
type. All patients with anaplastic tumors should be 
screened for TP53 mutations in the tumor, and if posi-
tive also in the germline after genetic counseling (if 
consented according to national guidelines) [25, 33]. 
Infants with SHH subgroup should be screened for ger-
mline PTCH1 [6] or SUFU mutations [30] after genetic 
counseling of the families.
4. Infants with group 3 medulloblastomas might be con-
sidered high risk independent of additional high-risk 
features. MYC status should be routinely assessed by 
FISH analysis and patients with tumors carrying MYC 
amplifications should be considered high-risk inde-
pendent of the presence of other high-risk features.
This universally applicable algorithm will help to 
increase diagnostic accuracy and to match disease risk with 
treatment intensity to the benefit of our patients.
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